[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100130303":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":31,"centralContacts":11,"locations":35,"responsibleParty":47,"collaborators":11,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":11,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":11,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":11,"overallStatus":69,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Novo Nordisk A\u002FS","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"SIBA 3W","EXPERIMENTAL",null,[13,14],"Drug: insulin degludec","Drug: placebo",{"label":16,"type":10,"description":11,"interventionNames":17},"SIBA OD",[13],[19,24,27],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","insulin degludec","Insulin degludec injected s.c. (under the skin) three times weekly",[9],{"type":20,"name":21,"description":25,"armGroupLabels":26,"otherNames":11},"Insulin degludec injected s.c. (under the skin) once daily for one week",[16],{"type":20,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"placebo","Placebo injected s.c. (under the skin) four times weekly",[9],[32],{"name":33,"affiliation":5,"role":34},"Global Clinical Registry (GCR, 1452)","STUDY_DIRECTOR",[36],{"facility":11,"status":11,"city":37,"state":11,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":11},"Neuss","41460","Germany","DE",{"type":42,"coordinates":43},"Point",[44,45],6.68504,51.19807,{"lat":45,"lon":44},{"type":48,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100130303","phase-1-a-trial-assessing-changes-in-blood-sugar-and-the-number-of-periods-where-supplementation-of-carbohydrate-is-needed-to-treat-low-blood-sugar-during-two-different-treatment-regimens-of-nn1250-in-type-1-diabetics-100130303",false,"NCT00964964","A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics","A Trial Assessing the Number of Hypoglycaemic Episodes and Glycaemic Variability During Two Different Regimens of SIBA 200 U\u002Fml in Subjects With Type 1 Diabetes","Inclusion Criteria:\n\n* Type 1 diabetes mellitus for at least 12 months\n* Glycosylated haemoglobin (HbA1c) between 7.5 and 9% (both inclusive)\n\nExclusion Criteria:\n\n* Donation or loss of more than 500 ml blood or plasma within three months prior to this trial\n* Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day) or not able or willing to refrain from smoking and the use of nicotine gum or transdermal nicotine patches during the in-house periods\n* Prior or current treatment with metformin or thiazolidinediones","ALL","18 Years","65 Years",{"count":60,"type":61},18,"ACTUAL","INTERVENTIONAL",[64],"PHASE1","This trial is conducted in Europe. The aim is to compare changes in blood sugar and the number of periods where carbohydrate supplementation is needed to treat low blood sugar, during two different treatments with NN1250 (insulin degludec), a soluble insulin basal analogue (SIBA) in subjects with type 1 diabetes.",[67,68],"Diabetes","Diabetes Mellitus, Type 1","COMPLETED","2013-11-26",{"date":72,"type":73},"2013-11-27","ESTIMATED",{"date":75,"type":11},"2009-08",{"date":77,"type":61},"2009-09",{"name":5,"class":6},1]